Cited by 995Opioid Use Disorder TreatmentSubstance Abuse Treatment and OutcomesPain Management and Opioid Use

The DOI matches its Crossref record; 36 of the 39 references it cites were found in a registry or an index.

Comparative effectiveness of different treatment pathways for opioid use disorder.

Open access

Wakeman, Sarah E., Larochelle, Marc R., Ameli, Omid, Chaisson, Christine E., McPheeters, Jeffrey Thomas, Crown, William H., Azocar, Francisca, Sanghavi, Darshak M.·2020·JAMA Network Open

DOI 10.1001/jamanetworkopen.2019.20622PMC PMC11143463

Open this paper in CoChat — free account Open PDF

Abstract

Importance: Although clinical trials demonstrate the superior effectiveness of medication for opioid use disorder (MOUD) compared with nonpharmacologic treatment, national data on the comparative effectiveness of real-world treatment pathways are lacking. Objective: To examine associations between opioid use disorder (OUD) treatment pathways and overdose and opioid-related acute care use as proxies for OUD recurrence. Design, Setting, and Participants: This retrospective comparative effectiveness research study assessed deidentified claims from the OptumLabs Data Warehouse from individuals aged 16 years or older with OUD and commercial or Medicare Advantage coverage. Opioid use disorder was identified based on 1 or more inpatient or 2 or more outpatient claims for OUD diagnosis codes within 3 months of each other; 1 or more claims for OUD plus diagnosis codes for opioid-related overdose, injection-related infection, or inpatient detoxification or residential services; or MOUD claims between January 1, 2015, and September 30, 2017. Data analysis was performed from April 1, 2018, to June 30, 2019. Exposures: One of 6 mutually exclusive treatment pathways, including (1) no treatment, (2) inpatient detoxification or residential services, (3) intensive behavioral health, (4) buprenorphine or methadone, (5) naltrexone, and (6) nonintensive behavioral health. Main Outcomes and Measures: Opioid-related overdose or serious acute care use during 3 and 12 months after initial treatment. Results: A total of 40 885 individuals with OUD (mean [SD] age, 47.73 [17.25] years; 22 172 [54.2%] male; 30 332 [74.2%] white) were identified. For OUD treatment, 24 258 (59.3%) received nonintensive behavioral health, 6455 (15.8%) received inpatient detoxification or residential services, 5123 (12.5%) received MOUD treatment with buprenorphine or methadone, 1970 (4.8%) received intensive behavioral health, and 963 (2.4%) received MOUD treatment with naltrexone. During 3-month follow-up, 707 participants (1.7%) experienced an overdose, and 773 (1.9%) had serious opioid-related acute care use. Only treatment with buprenorphine or methadone was associated with a reduced risk of overdose during 3-month (adjusted hazard ratio [AHR], 0.24; 95% CI, 0.14-0.41) and 12-month (AHR, 0.41; 95% CI, 0.31-0.55) follow-up. Treatment with buprenorphine or methadone was also associated with reduction in serious opioid-related acute care use during 3-month (AHR, 0.68; 95% CI, 0.47-0.99) and 12-month (AHR, 0.74; 95% CI, 0.58-0.95) follow-up. Conclusions and Relevance: Treatment with buprenorphine or methadone was associated with reductions in overdose and serious opioid-related acute care use compared with other treatments. Strategies to address the underuse of MOUD are needed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamanetworkopen.2019.20622

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figure 1. Probability of Opioid Overdose and Acute Care Use During the 3-Month Follow-up Period BH indicates behavioral health; CE, continuous enrollment; BH IOP, intensive behavioral health (intensive outpatient or partial hospitalization); IP detox/RTC, inpatient detoxification or residential services; and MOUD, medication for opioid use disorder.CC BY-NC-ND · PubMed Central

Figure 2. Probability of Opioid Overdose and Acute Care Use During the 12-Month Follow-up Period CE indicates continuous enrollment; MOUD, medication for opioid use disorder.CC BY-NC-ND · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.-C., Saunders, L. D., Beck, C. A., Feasby, T. E., & Ghali, W. A. (2005) · Medical Care · doi:10.1097/01.mlr.0000182534.19832.83 · Cited by 10,669
Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.
Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017) · BMJ · doi:10.1136/bmj.j1550 · Cited by 1,816
Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017
Scholl, L., Seth, P., Kariisa, M., Wilson, N. O., & Baldwin, G. T. (2018) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm675152e1 · Cited by 1,754
Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study
Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018) · Annals of Internal Medicine · doi:10.7326/m17-3107 · Cited by 1,076
Self-citation
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial
Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32812-x · Cited by 700
Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014
Zibbell, J. E., Asher, A. K., Patel, R. C., Kupronis, B. A., Iqbal, K., Ward, J. W., & Holtzman, D. J. (2017) · American Journal of Public Health · doi:10.2105/ajph.2017.304132 · Cited by 699
The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis
Ciccarone, D. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.01.010 · Cited by 677
National and state treatment need and capacity for opioid agonist medication-assisted treatment
Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302664 · Cited by 668
Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence: A 2-Phase Randomized Controlled Trial
Weiss, R. D. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.121 · Cited by 540
Medications for Opioid Use Disorder Save Lives
Mancher, M., & Leshner, A. (2019) · National Academies Press eBooks · doi:10.17226/25310 · Cited by 473

Show all 39 references

Sorted by citations

Items 901–995 of 995

Dyadic association between support persons’ attitudes towards medication for opioid use disorder and patients’ mental health outcomes
Moon, K. J., Burgette, L. F., Choi, J., Nameth, K., Shah, K., Watkins, K. E., & Osilla, K. C. (2026) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2026.113053
Addiction care outcomes between insured and state opioid response grant-funded patients in a Medicaid non-expansion state
Le, T. D. V., Reese, T. J., Wiese, A. D., Kast, K. A., Craig, R. L., Shah, M. V., Smith, M., von Horn, A. U., & Marcovitz, D. E. (2026) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2026.209901
Patient preferences for incentives in Contingency Management interventions in methadone treatment: A best-worst scale analysis
Dao, T. T. D., Nguyen, H. T., Trang, N. T., Phung, T. T., Hoang, V. H., Le, H. T., Pence, B. W., Le, G. M., Go, V. F.-L., & Miller, W. C. (2026) · PLoS ONE · doi:10.1371/journal.pone.0341359
Buprenorphine initiation from fentanyl using low-dose intramuscular ketamine: a pilot study
Engeriser, J. L., Hutch, T., Smith, C. L., Orme, Z., Chavers, E., & Grande, L. A. (2026) · Addiction Science & Clinical Practice · doi:10.1186/s13722-026-00649-3
Integrating Medications for Addiction Treatment into Assertive Community Treatment Teams: A Pilot Feasibility Study
Iheanacho, T., Ives, M. L., Lin, H., Rodis, E., DeLuca, D., & Dike, C. C. (2026) · Community Mental Health Journal · doi:10.1007/s10597-026-01602-z
Buprenorphine prescribing is increasingly delivered by primary care nurse practitioners to Medicaid beneficiaries
Turi, E. R., Lorenc, E., Fadeyibi, O., Johnson, J., Ryhal, C., Lim, S., Williams, S., Shen, L., Compton, P. A., & Candon, M. K. (2026) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000001258
Health Plan Disenrollment and Mortality After Initiation of Medications for Opioid Use Disorder
Nguyen, A. P., Binswanger, I. A., Narwaney, K. J., Goodrich, G. K., Christine, P. J., Campbell, C. I., Xu, S., Loree, A. M., & Glanz, J. M. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2026.0021
How do we promote methadone and buprenorphine initiation among people with opioid use disorder?
Welch, A. E., Tuazon, E. D., & Mantha, S. (2026) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2026.2639477
State Prior Authorization Prohibitions and Buprenorphine Retention Among Privately Insured Patients
Hu, J., Kapadia, S. N., Zhang, H., Jalali, A., Underhill, K., Andrews, C. M., & Bao, Y. (2026) · JAMA Health Forum · doi:10.1001/jamahealthforum.2026.0012
Complementary services improve recovery outcomes among college students with alcohol or other drug related use disorders
Qeadan, F., Lipkens, N. R., & Tingey, B. (2026) · Scientific Reports · doi:10.1038/s41598-026-43756-6
Expert recommendations for training peer workers to provide non-abstinent recovery support: A real-time Delphi study
Pasman, E., Drazdowski, T. K., Mabila, P., Patterson, D., McCabe, S. E., Resko, S. M., & Sheidow, A. J. (2026) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2026.210097
Characterizing the Association Between Traumatic Brain Injury and Discontinuation of Medications for Opioid Use Disorder in a Commercially Insured Adult PopulationPreprint
Adams, R. S., Reif, S., & Morgan, J. R. (2026) · OSF Preprints (OSF Preprints)
Comparing two strategies to support the implementation of evidence-based practices for substance use disorders in VA’s permanent supportive housing program: a protocol for a type 3 hybrid cluster-randomized controlled trial
Gabrielian, S. E., Chang, E. T., Treichler, E. B. H., Barnard, J. M., Nelson, R. E., Wong, M. S., JACKSON, N. J., & Finley, E. P. (2026) · Implementation Science · doi:10.1186/s13012-026-01498-z
Single state agency licensure requirements for substance use disorder treatment programs in the United States: results of a national survey
Yelton, B., Westlake, M. A., Abraham, A. J., Grogan, C. M., Hinds, O. M., & Andrews, C. M. (2026) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-026-00724-7
Patient Characteristics Associated with Successful Initiation of Extended-Release Naltrexone in the X:BOT Trial
Potter, K. M., Greiner, M. G., Shulman, M., Scodes, J. M., Choo, T.-H. J., Pavlicová, M., Novo, P., Fishman, M. J., Lee, J. D., Rotrosen, J., et al. (2026) · Substance Use & Misuse · doi:10.1080/10826084.2026.2617963
Implementation of low-dose buprenorphine induction at a syringe services program
Hauschild, M. H., Warp, P. V., Eger, W. H., Hood, R., Bahamón, M., Forrest, D. W., Bartholomew, T. S., Suarez, E., Chueng, T. A., Ciraldo, K. J., et al. (2026) · Addiction Science & Clinical Practice · doi:10.1186/s13722-026-00661-7
Marqueurs moléculaires de l'escalade de consommation d'héroïne et de la rechute sous un traitement de substitution, la méthadone
Clémenceau, L. (2023) · doi:10.70675/4ae5cdecz30c8z4ef1z8279zbbc222444aad
Trends in Buprenorphine and Methadone Initiation for Opioid Use Disorder Among Patients Using Fentanyl: A Mixed-Methods Analysis From an Inpatient Addiction Consult Service
Kee, D. P., Feder, K. A., Wood, L., Garneau, W. M., & Buresh, M. E. (2026) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001693
Does perceived stigma impact opioid use disorder treatment uptake? A cross-sectional secondary analysis of buprenorphine engagement among syringe service program participants
Campbell, B., Riback, L. R., Portillo, J. G., Maricic, S., & Fox, A. D. (2026) · Addiction Science & Clinical Practice · doi:10.1186/s13722-026-00665-3
Adiposity and inflammation mediate altered metabolic profiles in individuals with opioid use disorderPreprint
Li, X., Manza, P., Wang, G., Giddens, N. T., Belcher, A. M., Schwandt, M. L., Diazgranados, N., Lynch, K. G., Volkow, N. D., Shi, Z., et al. (2026) · medRxiv · doi:10.64898/2026.04.13.26350800
Using Multistate Models and Qualitative Interviews to Comprehensively Characterize Substance Use Disorder Care Transitions in a US Health Care System: Protocol for a Mixed-Methods Study
Glass, J. E., Wong, E. S., Beatty, T. C., Bobb, J. F., Brown, R., Fishman, P. A., Idu, A., Lin, J. Y., Matson, T. E., Palazzo, L. G., et al. (2026) · JMIR Research Protocols · doi:10.2196/93043
Community-informed design of personalized patient-facing materials to facilitate ED-initiated treatment of opioid use disorder
Nath, B., Levy, D. R., Strycharz, H., Sherak, R. A. G., Gilkes, J., Oladele, C., Sarpong, D. F., Schoenfeld, E. M., Hawk, K. F., Panthagani, K. M., et al. (2026) · PEC Innovation · doi:10.1016/j.pecinn.2026.100478
Evaluating risk factors and protective clinical interventions for opioid use disorder and overdose in American Indian/Alaska Native populations
Qeadan, F., Madden, E. F., Tingey, B., Egbert, J., Venner, K. L., & English, K. C. (2026) · Journal of Ethnicity in Substance Abuse · doi:10.1080/15332640.2026.2657000 · Cited by 1
Overdose Prevention Education and Medication for Opioid Use Disorder in School-Based Health Centers: A Qualitative Exploration
Renehan, C. M., Alim, A. M., Cogan, A., Wiggins, M., Weinberger, E., Carney, B. L., Alves, J., Ventura, A. S., Lopes, M. D., & Bagley, S. M. (2026) · Substance Use & Addiction Journal · doi:10.1177/29767342261442454
Opioid agonist treatment in the era of fentanyl: Reflections from the AATOD conference, Philadelphia 2025
Maremmani, I. (2025) · Heroin addiction and related clinical problems · doi:10.62401/2531-4122-2025-33
Medicaid Managed Care Plan Alignment With State Substance Use Disorder Treatment Coverage Requirements
Feltus, S. R., Andrews, C. M., Peterson, L., Grogan, C. M., Abraham, A. J., Hinds, O. M., & Stewart, M. T. (2026) · Milbank Quarterly · doi:10.1111/1468-0009.70083
Real-world effectiveness of medication-assisted treatment and psychotherapy for opioid use disorder: a national multi–health care organization analysis
Graziane, N. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1741907
Would we, could we? Measuring attitudinal and capacity barriers to supporting recovery housing residents on medication for opioid use disorder
Winograd, R., Park, B., Ghonasgi, R., Paschke, M., & Mericle, A. A. (2026) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2026.210009
Access to Medications for Opioid Use Disorder Among Veterans With Homeless Experience in Permanent Supportive Housing
Hsu, M., Panadero, T. J., Mooney, L. J., Kim, D., Lawrence, D., Yuan, A., Siddarth, P., & Gabrielian, S. E. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.10831
Exploring the Importance of Demographic, Familial and Situational Risk Factors for the Choice of Specific Psychoactive Substances
Lassmann, J., Varkovic, A., Lipska, A., Popravko, M., Tomaszewska, J., Pawłowski, K., Milewska, A., Wiergowski, M., & Waszak, P. M. (2026) · Journal of Drug Issues · doi:10.1177/00220426261446618
Harm-reduction Approaches for Alcohol Use: An Update to the Landmark Marlatt & Witkiewitz (2002) and Witkiewitz & Marlatt (2006) Narrative Reviews
Collins, S. E., & Clifasefi, S. L. (2026) · Current Addiction Reports · doi:10.1007/s40429-026-00750-2
Associations Between Medication for Opioid Use Disorder and Family Functioning in Child Welfare-Involved Families
Hall, M. T., Hardy, G. C., Brooks, A. J., & Winters, A. (2026) · Child Maltreatment · doi:10.1177/10775595261453528
Substance Use Services at Child Psychiatry Access Programs
Ball, A., Lee, C. M., Tripp, P., Sarvet, B. D., & Congdon, J. L. (2026) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2026.03.003
Upstream Determinants of Opioid Risk: Trauma, Stigma, and Social Capital in the Risk Environment Qualitative Literature
Webster, L. R., & Eichberg, S. (2026) · Springer eBooks · doi:10.1007/978-3-032-23135-2_14
Failure to Treat Opioid Use Disorder and Opioid Withdrawal Associated with Patient-Directed Discharge in People with Injection-Related Infections
Traver, E. C., Iyalomhe, O. E., Ramadhani, H. O., Stevens, J., Derenoncourt, M., Vaish, I. K., Flores, H. E., Fujita, A. W., Raman, S., Steck, A., et al. (2026) · Journal of General Internal Medicine · doi:10.1007/s11606-026-10514-3
The Implementation of Medications for Opioid Use Disorder in Recovery Residences: Assessing the Impact of the Consolidated Framework for Implementation Science Constructs
Nichols, C. (2026) · Substance Use & Misuse · doi:10.1080/10826084.2026.2670603
The Socioeconomic Impact of Long-Acting Injectable Buprenorphine
Rasche, S., Batchelor, G., Montgomery, C., Sumnall, H., & Mogford, D. V. (2026) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s590462
Attributable Costs
Schneider, J. E. (2026) · Global perspectives on wealth and distribution · doi:10.1007/978-3-032-20355-7_6
Abatement Costs
Schneider, J. E. (2026) · Global perspectives on wealth and distribution · doi:10.1007/978-3-032-20355-7_7
Reducing Buprenorphine Misinformation as a Strategy to Improve Adoption in Primary Care
Bogart, S. M., Fenstemaker, C., Abrams, E. A., King, K., Tripathy, R., Shalash, J., & Franz, B. A. (2026) · Substance Use & Misuse · doi:10.1080/10826084.2026.2672651
Treatment outcomes of an integrated treatment model for patients with co-occurring opioid use and schizophrenia spectrum disorders
Deng, Y., Seman, M., Ma, C., Moomaw, S., Berry, J. H., Durham-Vold, K., Tonkovich, K., Hustead, J. D., Wen, S., & Zheng, W. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1826744
Use of Medication for Addiction Treatment Among Physicians and Pharmacists Monitored for Substance Use Disorder by One State Physician Health Program
Araujo, C. N. P., Polles, A., & Merlo, L. J. (2026) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001733
Using an ethical lens in frontline alcohol and other drug services: Enhancing access to care
Silkoff, D., McDougall, R. J., Chenhall, R. D., Henderson, C. R., & Naren, T. (2026) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2026.105401
Comparative outcomes of opioid withdrawal management strategy in patients with injection-related bacteremia
Handy, S., Garton, T., Schwell, I., Maitin, A., Induru, V., Rahman, Y., & Yeung, H. (2026) · Journal of Addictive Diseases · doi:10.1080/10550887.2026.2685063
“We Have a Moral Commitment to the Community to Sustain It”: Exploring Determinants of Strategy Sustainment After the HEALing Communities Study
Jadovich, E., Davis, J., Andrews-Higgins, S., Back-Haddix, S., Goetz, M., Kim, E., Mayotte, C., Voss, L. A., Walker, D. M., Beers, D., et al. (2026) · Implementation Research and Practice · doi:10.1177/26334895261450989
Policy and Payment Factors Influencing Adoption of Low-Barrier Buprenorphine Treatment
Lowenstein, M., Davis, M. H., Suhail-Sindhu, S., McMurtrie, G., Grande, D., Hinckley, J., & Aronowitz, S. V. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.18878
The Economic burden of opioid-related serious adverse events and undertreatment of acute pain in the United States
Hackworth, J. C., Schneider, J. E., Valle, M. L. D., Fam, D. S., Ohsfeldt, R. L., Offidani, E., & Potenziano, J. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1824038
“The alternative is they’re not getting care at all”: a qualitative interview study of opioid use disorder treatment providers’ perspectives on quality and appropriateness of telehealth for buprenorphine access
Zucker, N., Flores, E., Mandell, D. S., Clapp, J. T., & Aronowitz, S. V. (2026) · Harm Reduction Journal · doi:10.1186/s12954-026-01474-2
Self-reported cannabis use to manage opioid withdrawal symptoms and reductions in opioid use among people who use unregulated opioids: a cross-sectional analysis
McAdam, E., Reddon, H., Socias, M. E., Lake, S., Hayashi, K., DeBeck, K., Walsh, Z., & Milloy, M. (2026) · Journal of Cannabis Research · doi:10.1186/s42238-026-00458-0
PF5190457 reduces fentanyl intake and seeking with a low risk pharmacological profile in male rats
Merritt, C. R., Salinsky, L. M., Garcia, E. J., Fox, R. G., Chapman, H. L., Linares, J. J., Russell, W. K., Moeller, F. G., Anastasio, N. C., & Cunningham, K. A. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.104978
Concurrent Use of Extra‐Medical Medication for Opioid Use Disorder Among Adults Prescribed Methadone or Buprenorphine: A Cohort Study of Urban Adults Who Have Injected Drugs
Moon, K. J., Genberg, B. L., Astemborski, J., German, D., Kirk, G. D., Mehta, S. H., & Feder, K. A. (2026) · Drug and Alcohol Review · doi:10.1111/dar.70204
Exploring Diversion Concerns as a Modifiable Buprenorphine-prescribing Barrier Among Primary Care Professionals
Abrams, E. A., Fenstemaker, C., King, K., Rausch, J., Tripathy, R., Shalash, J., & Franz, B. A. (2026) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001738
Neurobiological and Behavioral Consequences of Prenatal Methadone or Buprenorphine Exposure: Insight From Animal Models
Nyberg, H., & Andersen, J. M. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70499
How do services offered within opioid treatment programs vary based on state methadone policies?
Lindenfeld, Z., Krawczyk, N., Taylor, E. A., Agniel, D., & Cantor, J. H. (2026) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2026.210062
“In My Community, if You’re an Addict, People Don’t Just Look Down on You for the Drugs, but for Being Black, Too”: Black and Latine Methadone Patients’ Experiences Around Addiction, Methadone Treatment, and Intersectional Stigma
Ward, A. M., Wood, T., Gerke, D., Walters, S., Williams, J., Clement, D., Katundu, M., Ferguson, D., Morrison, K., Alnashri, Y., et al. (2026) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-026-03074-z · Cited by 1
Cost-Effectiveness of Emergency Department–Initiated Buprenorphine With Rapid Follow-Up for Opioid Use DisorderPreprint
Christie, A. C., Idowu, E. O., Udayan, U., Rafee, A. R., Allen, D. H., Madavan3, S., Grimadeau, C., Loyd, K., Whitley, K., & Tanwar, A. (2026) · Research Square · doi:10.21203/rs.3.rs-9486873/v1
Drug Use, Treatment, and Hopes for the Future: A Qualitative Study of Patients on Methadone Who Use Cocaine in the Age of Fentanyl
French, R., Alexander, K., Sharma, A., Gryczynski, J., Schachter, A., & Schwartz, R. P. (2026) · Substance Use & Addiction Journal · doi:10.1177/29767342261460411
Buprenorphine initiation by a street medicine program is associated with reduced opioid-related emergency department utilization among people experiencing homelessness
Wallace, C. R., King, J., Nichols, T. C., Abrams, E. A., Shaw, S., Hoeflinger, N., Mullangi, V., Sandoval, B., Matzke, J., Kauffman, E., et al. (2026) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2026.113258
Substance Withdrawal
Lowenstein, M., & Huo, S. (2026) · Springer eBooks · doi:10.1007/978-3-032-22660-0_2
Buprenorphine-Naloxone vs Extended-Release Naltrexone Following Opioid Withdrawal Treatment
Hsu, H., Lodi, S., Yan, S., Bovell-Ammon, B. J., Christine, P. J., Tilhou, A. S., Bernson, D., Novo, P., Lee, J. D., Rotrosen, J., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.23280
Self-citation
Predictive Models for Time to First Opioid Use Disorder or Opioid Overdose Among Older Adults
Chiang, C., Brock, G., Schmidt, S. O., Fillingim, R. B., Schmidt, S., & Wei, Y. J. (2026) · Journal of General Internal Medicine · doi:10.1007/s11606-026-10628-8
Sleep Disturbance in Opioid Use Disorder: Systematic Review of Insomnia Prevalence and Sedative-Hypnotic Utilization
Chekani, F., Lü, Y., Jain, A., & Sharma, S. (2026) · Substance Use & Misuse · doi:10.1080/10826084.2026.2703850
Enhancing Access to Methadone Treatment in Three HEALing Communities Study Sites: A Spatial and Geostatistical Study
Lewis, O., Srinivasan, S., Shrestha, S., Harris, D. R., Barboza‐Salerno, G., Rock, P. J., Walley, A. Y., Samet, J. H., & Stopka, T. J. (2026) · Substance Use & Misuse · doi:10.1080/10826084.2026.2679711
Continuity of Medications for Opioid Use Disorder in States With and Without Medicaid Prescription Cap Policies
Moyo, P., George, M., Hughes, L. D., Shireman, T. I., Donohue, J. M., Andrews, C. M., Peterson, L., & Hughto, J. M. W. (2026) · Medical Care · doi:10.1097/mlr.0000000000002366
Variation in knowledge and attitudes among overdose prevention collaborations: Insights from fatality review teams
Ray, B. R., Gillenwater, L. A., Dir, A. L., Ouyang, F., Monahan, P. O., McGladrey, M., Reda, K., & Aalsma, M. C. (2026) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2026.113287
Management of Patients on Medications for Opioid Use Disorder in the Perioperative or Peripartum Setting
Awuku, B., Lai, B., Oberhelman, S. S., & Liu, M. (2026) · Advances in Anesthesia · doi:10.1016/j.aan.2026.06.009
Implementation of mobile medical units for naloxone distribution and MOUD linkage in Ohio’s HEALing Communities Study: a community case study
Rubi, S., Ingram, T., Brown, J. L., Sprunger, J. G., Matherny, P., Lyons, M. S., & Winhusen, T. M. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1883800
Policies and practices addressing medication and substance use in recovery housing: findings from a nationally representative survey
Mericle, A. A., Subbaraman, M. S., Patterson, D., Li, L., Barrett, C., & Karriker‐Jaffe, K. J. (2026) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2026.2705219
Reframing drug abuse through science: A call for evidence-based policy and practice (Scientific commentary)
ERUBU, A. S. (2026) · Brazilian Journal of Science · doi:10.14295/bjs.v6i2.952
Characterizing Rural Substance Use Treatment Experiences Among Individuals Under Community Correctional Supervision
Rowell‐Cunsolo, T. L., Blanford, C., Seal, D., Jenkins, W. D., Mixson, L. S., Hoover, D. B., Stopka, T. J., Oser, C. B., Friedmann, P. D., Smith, G. S., et al. (2026) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001758
The (Mis)alignment of Narcotics Anonymous and the Communication Theory of Resilience
Wolfe, B. H., & Hintz, E. A. (2026) · Springer eBooks · doi:10.1007/978-3-032-31162-7_10
Markov computational modeling to predict opioid vs. money choice and behavioral effort in regular heroin usersPreprint
Jhand, A. S., & Greenwald, M. K. (2026) · medRxiv · doi:10.64898/2026.08.18.26360767
College students’ attitudes toward multiple pathways recovery communities inclusive of abstinent and nonabstinent goals
Pasman, E., Marks, E., Burson, N., Vest, N. A., Broman, M. J., Kuentzel, J. G., & Resko, S. M. (2026) · Journal of American College Health · doi:10.1080/07448481.2026.2719630
Roads to Recovery Capital: Associations Between Posttraumatic Stress Disorder and Recovery Capital Among Individuals with Opioid Use Disorder
Newberger, N. G., Ferguson, J. J., Egan, A., Sheldon, D. N., Chasten, N. T., Seebold, B. A., Avila, A. L., Rich, J. D., & Weiss, N. H. (2026) · Journal of Dual Diagnosis · doi:10.1080/15504263.2026.2720397
Opioid Use Disorder Outcomes Following Inpatient Opioid Withdrawal Management
Bailey, G. L., Lee, J. D., Nunes, E. V., Tofighi, B., Novo, P., King, J., Liu, D., Farkas, S., Gauthier, P. R., Thomas, A. A., et al. (2026) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001710
National Quality Measure Fails to Capture Most Emergency Department Patients With Opioid Use Disorder
Anderson, E. S., Heeney, M. E., Rusoja, E., Katsin, H., Howard, N., Cruz, D. L., Patregnani, M., Ullal, M., Hawk, K., Venkatesh, A., et al. (2026) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001774
Brixadi for Stimulant Use Disorder: Evolving Pharmacologic Considerations and Clinical Implications.
Sawaya, M. F., McNulty, M. E., Germain, C. J. S., Hachem, I. A., Calix, M. S., Lormand, R. M., McComb, N., Shehab, A. A. A., Wrightson, J., Anwar, A. I., et al. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03772-4
Unveiling Women’s Leadership in Addiction Advocacy
Eggert, K. F. (2026) · Emerald Group Publishing Limited eBooks · doi:10.1108/978-1-83662-770-820261004
Specific Mental Disorder Comorbidities and MOUD Receipt for Opioid Misuse: Lower Receipt for Persons with Psychotic Disorders
Moore, J., Renn, T., & Killian, M. (2026) · Journal of Dual Diagnosis · doi:10.1080/15504263.2026.2729324
Effects of Alpha-Band Binaural Beat Entrainment on Anxiety and Aggression in Men With Opioid Use Disorder: A Randomized Sham-Controlled Trial Running Title: Binaural Beat Entrainment in Opioid Use DisorderPreprint
Soleimanifar, D., & Mansouriyeh, N. (2026) · Research Square · doi:10.21203/rs.3.rs-10781456/v1
Medications for opioid use disorder receipt in intensive care patients with opioid use disorder—A statewide cohort study
Quaye, A., Westgard, L. K., Richard, J. M., & Wurcel, A. G. (2026) · Journal of Opioid Management · doi:10.5055/jom.1003
Visiting Nurse Services-facilitated Outpatient Low-dose Buprenorphine Initiation and Engagement in Severe Mental Illness and Ongoing Fentanyl Use: A Case Report
Cruz, F. A., Castillo, J. C., & Palmer, N. P. (2026) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001784
Racial and Ethnic Disparities in Buprenorphine and Naloxone among Medicaid Beneficiaries after Emergency Department Visits and Hospitalizations
Khidir, H., Nédélec, L., Sebok‐Syer, S. S., Sabbatini, A. K., Shin, I., Melnick, E. R., & Lin, M. (2026) · Journal of General Internal Medicine · doi:10.1007/s11606-026-10838-0
Impact of opioid agonist therapies on non-fatal and fatal overdose: treatment patterns among individuals with opioid use disorder in Ontario, Canada
Lee, K., Lam, V., Nicolle, J., Drolet, M., Abdel-Sattar, M., Ng, G., & Snider-Adler, M. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1894981
What is the Relationship Between Addiction Medications and Healthcare Utilization?
Bernstein, E. Y. (2026) · Journal of General Internal Medicine · doi:10.1007/s11606-026-10885-7
A Human Rights Analysis of Therapeutic Psychedelic Drug Prohibition and Cognitive Liberty in MauritiusPreprint
Ramburruth, H. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.7556558
Health insurance and MOUD: predicting OUD treatment success
White, A. S., & Manuel, J. I. (2026) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-026-00772-z
County-level context and differential policy impacts on buprenorphine use among medicaid enrollees with opioid use disorder in Kentucky, 2018–2025
Miracle, D. K., Slavova, S. S., Freeman, P. R., & Tarima, S. S. (2026) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2026.113394
Type of medication for opioid use disorder is associated with distinct risk profiles among an urban community sample of people who use opioidsPreprint
Yi, G. T., Dayton, L., Feder, K. A., Sugarman, O. K., Falade-Nwulia, S., Uzzi, M., & Latkin, C. A. (2026) · Research Square · doi:10.21203/rs.3.rs-10252075/v1
Exploring the addictive potential of α-methylfentanyl and acetyl-α-methylfentanyl in animal models
deli, X., xuesong, S., kaixi, L., Kuai, L., Luo, X., Chen, Y., Di, B., & Xu, P. (2026) · Psychopharmacology · doi:10.1007/s00213-026-07185-7
Acceptability and feasibility of an adaptive walking program for Veterans with chronic pain and opioid use disorder
MacLean, R. R., Wolkowicz, N. R., Wesolowicz, D. M., Schrader, S. W., Szollosy, S. K., Meyerovich, J. V., Martino, S., Allen, K. D., Gueorguieva, R. V., Sofuoglu, M., et al. (2026) · Behavior Therapy · doi:10.1016/j.beth.2026.10.002
Substance Use Treatment and Recovery Services for Emerging Adults in the US: Integrating Developmental Considerations for Effective Intervention and Research
Sheidow, A. J., Drazdowski, T. K., Pasman, E., Wenzel, K. R., Gallardo, K. R., Jurinsky, J., Kelly, L. M., McCart, M. R., Hayes, B. B., Lewis, L. E., et al. (2026) · Emerging Adulthood · doi:10.1177/21676968261493641
Statewide availability of pharmacies in Georgia prepared to dispense buprenorphine or naloxone: A secret shopper study
Hudson, J., Giordano, N. A., Maurer, A., Getz, T., Nkansah, P., Sophie, B., Maisuria, D., Morrison, H., Morgan, R., Kiernan, E. A., et al. (2026) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2026.113406
“Building the connection route to help”: a qualitative study of opioid use disorder recovery processes for black women age 18–30
Porter, T. S., Godden, M., Carrico, S., & Draughon, J. E. (2026) · Journal of Ethnicity in Substance Abuse · doi:10.1080/15332640.2026.2749554
Pharmacotherapy and behavioral treatment for substance use disorders during pregnancy and postpartum: a narrative review
Jones, H. E., & Ramage, M. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2756492

Authors: Wakeman, S. E., Larochelle, M. R., Ameli, O., Chaisson, C. E., McPheeters, J. T., Crown, W. H., Azocar, F., & Sanghavi, D. M.
Affiliations: Harvard University (US)
Boston University (US)
Integrated Programs, OptumLabs Inc, Cambridge, Massachusetts
Optum (United States) (US)
Department of Research, OptumLabs, Cambridge, Massachusetts
Department of Research, Optum Behavioral Health, Cambridge, Massachusetts
UnitedHealth Group (United States) (US)
Corresponding author: Wakeman, Sarah E.
ORCID: Wakeman, Sarah E.
Larochelle, Marc R.
Ameli, Omid
Chaisson, Christine E.
Crown, William H.
Azocar, Francisca
Sanghavi, Darshak M.
Venue: JAMA Network Open
Publisher: American Medical Association (AMA)
Published: 2020-02-05
Volume: 3
Issue: 2
Pages: e1920622
ISSN: 2574-3805 (ISSN-L)
DOI: 10.1001/jamanetworkopen.2019.20622
PMC: PMC11143463
OpenAlex: W3005454586
Cited by: 995
References: 39
Citations by year: 2026: 137 · 2025: 170 · 2024: 192 · 2023: 161 · 2022: 158 · 2021: 128 · 2020: 49
FWCI: 92.82
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc-nd
Locations: JAMA Network Open (publishedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Funders: Massachusetts General Hospital
School of Medicine, Boston University (1UL1TR001430)
Laura and John Arnold Foundation
Office of National Drug Control Policy (G1799ONDCP06B)
Hamilton Health Sciences Foundation
National Institutes of Health (UL1TR001430)
Centers for Disease Control and Prevention (U01CE002780)
U.S. Food and Drug Administration (HHSF223200910006I)
Substance Abuse and Mental Health Services Administration (1H79TI081442-01)
National Institute on Drug Abuse (K23DA042168, R01DA044526, UG1DA015831, G1799ONDCP06B)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
Keywords: opioid use disorder, medication-assisted treatment, buprenorphine, methadone, naltrexone, inpatient detoxification, residential treatment, opioid overdose, acute care utilization, treatment pathways, comparative effectiveness, real-world evidence, injection-related infections
MeSH terms: Adolescent, Adult, Analgesics, Opioid, Behavior Therapy, Buprenorphine, Female, Humans, Male, Methadone, Middle Aged, Opioid-Related Disorders, Retrospective Studies, United States, Proportional Hazards Models, Substance Abuse Treatment Centers, Treatment Outcome, Critical Pathways, Young Adult, Comparative Effectiveness Research, Opiate Substitution Treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Comparative effectiveness of different treatment pathways for opioid use disorder.

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks